The British pharmaceutical multinational GlaxoSmithKline (GSK) has negotiated the payment of 3.4 billion dollars to the US Treasury, thus avoiding the tax avoidance trial, which should have started next February. At the same time, GSK dropped its $1.8 billion tax return claim.
